Abstract Objectives The prognosis of patients with Small Cell Lung Cancer (SCLC) can be predicted by their Lymph Node (LN) status. The authors aimed to assess the correlations between SCLC survival and number of LN Ratio (LNR), positive LN (pLNs), and Logarithmic Odds of positive LN (LODDS). Methods This cohort study retrospectively included 1,762 patients with SCLC from the SEER database 2004‒2015. The X-tile software was used to determine the cutoff values for pLNs, LNR, and LODDS. The correlations between pLNs, LNR, and LODDS with Overall Survival (OS) and Cancer-Specific Survival (CSS) were explored using Cox regression analysis. The study used the C-index to assess the predictive value of LNR, pLNs, and LODDS on survival. Results Among these 1,762 patients, 121 (6.87%) were alive, 1,641 (93.13%) died, and 1,532 (86.95%) died of SCLC. In univariable COX analysis, LNR, pLNs, and LODDS all showed a correlation with CSS and OS (p < 0.05). In multivariable COX analysis, only patients with LODDS (> 0.3 vs. ≤ 0.3) were related to both worse OS (HR = 1.28, 95% CI 1.10‒1.50) and CSS (HR = 1.29, 95% CI 1.10‒1.51), but no correction was observed between LNR and pLNs and survival (p > 0.05). The C-indices for predicting OS for LODDS were 0.552 (95% CI 0.541‒0.563), for LNR 0.504 (95% CI 0.501‒0.507), and for pLNs 0.527 (95% CI 0.514‒0.540). Moreover, the association between LODDS and prognosis in SCLC patients was significant only in patients with LN stage N1 and N2, but not in stage N3. Conclusion LODDS may be better than other LN assessment tools at predicting survival in SCLC patients. (SCLC (LN status , (LNR) (pLNs) . (LODDS) 1762 1 762 1,76 20042015 2004 2015 2004‒2015 Xtile X tile (OS CancerSpecific Specific (CSS analysis Cindex C index 12 6.87% 687 6 87 (6.87% alive 1641 641 1,64 93.13% 9313 93 13 (93.13% 1532 532 1,53 86.95% 8695 86 95 (86.95% p 0.05. 005 0.05 0 05 0.05) ( 03 3 0. vs HR 128 28 1.28 1.10‒1.50 110150 10 50 129 29 1.29 1.10‒1.51, 110151 1.10‒1.51 51 1.10‒1.51) Cindices indices 0552 552 0.55 (95 0.541‒0.563, 05410563 0.541‒0.563 541 563 0.541‒0.563) 0504 504 0.50 0.501‒0.507, 05010507 0.501‒0.507 501 507 0.501‒0.507) 0527 527 0.52 0.514‒0.540. 05140540 0.514‒0.540 514 540 0.514‒0.540) Moreover N N2 N3 (LNR (pLNs (LODDS 176 76 1,7 2004201 200 201 2004‒201 6.87 68 8 (6.87 164 64 1,6 93.13 931 9 (93.13 153 53 1,5 86.95 869 (86.95 00 0.0 2 1.2 1.10‒1.5 11015 5 055 55 0.5 (9 0541056 0.541‒0.56 54 56 050 0501050 0.501‒0.50 052 52 0514054 0.514‒0.54 17 7 1, 200420 20 2004‒20 6.8 (6.8 16 93.1 (93.1 15 86.9 (86.9 1. 1.10‒1. 1101 054105 0.541‒0.5 050105 0.501‒0.5 051405 0.514‒0.5 20042 2004‒2 6. (6. 93. (93. 86. (86. 1.10‒1 110 05410 0.541‒0. 05010 0.501‒0. 05140 0.514‒0. 2004‒ (6 (93 (86 1.10‒ 11 0541 0.541‒0 0501 0.501‒0 0514 0.514‒0 (8 1.10 054 0.541‒ 0.501‒ 051 0.514‒ 1.1 0.541 0.501 0.514 0.54 0.51

Abstract To explore characteristics of patients with pneumonia infected by 2019 Novel Coronavirus (COVID-19) in 2019 outside Hubei Province, China. 40 patients with pneumonia infected by COVID-19 which were confirmed by COVID-19 nucleic acid test were included. Procalcitonin (PCT), serum amyloid A (SAA), C-reactive protein (CRP) and computed tomography (CT) manifestations were analyzed. 40% of patients had clear contact history with Wuhan or other areas of Hubei Province. 60% of patients were clustered diseases and 40% were imported cases. 75% of patients had initial fever, 7.5% had cough, 5% had sore throat at first. 45% had decreased lymphocyte count, 72.5% and 55% patients had increased levels of SAA and CRP. 72.5% of the patients showed multiple ground glass lesions in one or two lungs on chest CT. 90% of the patients with pneumonia are of the common type, and α-interferon atomization inhalation combined with Lopinavir/Ritonavir tablets were given to patients during treatment. 62.5% of the patients were treated with antibiotics, and 15% with hormone. All patients improved after treatment, and 14 patients were cured and discharged. Family cluster infection and asymptomatic infection may be the main way of spreading of COVID-19 pneumonia outside Hubei Province in China.